Recommendation of the President – Brukinsa (zanubrutinib)

On 21 August 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 88/2024 on the evaluation of the drug Brukinsa (zanubrutinib) within the framework of the drug program “Treatment of patients with B-cell lymphoma (ICD-10: C82, C83, C85)”

Publication in Public Information Bulletin (BIP) >>